Maia Biotechnology Inc (MAIA)

[crudeoil24]

MAIA Biotechnology, Inc. is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. The Company’s pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers. The Company's THIO (6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is a telomere-by-telomerase targeting agent for the treatment of multiple cancer types. THIO is followed by Libtayo for the treatment of advanced non-small-cell lung cancer. The Company's 2nd-generation program is engaged in discovering new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. The 2nd-generation pipeline of potential telomere-targeting agents includes five compounds that have undergone in vitro inhibitory testing in five cancer models. The Company's subsidiary is MAIA Biotechnology Australia Pty Ltd.